Claim: Etomoxir was in clinical development for the treatment of lung cancer and went through preclinical trials by Byk Gulden laboratories (now Altana Pharma AG) from 1981 to 1984.
Evidence: Etomoxir has already been through phase II clinical development for the treatment of type 2 diabetes and heart failure.